ResearchMoz presents this most up-to-date research on PharmaPoint: Microvascular Complications of Diabetes – Spain Drug Forecast and Market Analysis to 2022.
The entire market for microvascular complications of diabetes (MCD) diabetic nephropathy, retinopathy, and neuropathy is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.
The uptake of drugs receiving additional approval for diabetic retinopathy/DME, such as Eylea, Iluvien and Ozurdex, will further drive sales in the MCD market. A dip in sales in the diabetic neuropathy market will happen from mid-2014 due to patent expiry of Cymbalta. Another dip in sales in the diabetic neuropathy segment will happen around 2018, when Lyricas patent expires.
Overview of MCD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in Spain from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting the Spain MCD market.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=186890
Table of Content
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
3 Disease Overview 14
3.1 Etiology and Pathophysiology 16
3.1.1 Diabetic Nephropathy 16
3.1.2 Diabetic Retinopathy 18
3.1.3 Diabetic Neuropathy 19
3.2 Prognosis 20
3.3 Quality of Life 21
3.4 Symptoms 22
4 Disease Management 23
4.1 Treatment Overview 23
4.1.1 Diagnosis and Referrals 23
4.1.2 Screening 25
4.1.3 Treatment Guidelines 26
4.2 Spain 33
4.2.1 Diagnosis 33
4.2.2 Clinical Practice 34
For More Information Kindly Contact:
Mr. Nachiket Ghumare,
USA-Canada Toll Free: 866-997-4948
Follow us on LinkedIn @ http://bit.ly/1TBmnVG